Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 5, 2007, Pages

  Edelman, Steve V ^a   Garg, Satish ^b   Kolterman, Orville G ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PRAMLINTIDE;

ADJUVANT THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMYLOID; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 34247500836     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0506     Document Type: Note

References (11)

1. Monnier L (2007) Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes? Nat Clin Pract Endocrinol Metab 3: 332-333
2. McCall AL et al. (2006) A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 8: 644-653
3. Weyer C et al. (2003) Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dosetiming study. Diabetes Care 26: 3074-3079
4. Amiel SA et al. (2005) The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 7: 504-516
5. Heise T et al. (2004) Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. Metabolism 53: 1227-1232
6. Nyholm B et al. (1996) Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81: 1083-1089
7. Nyholm B et al. (1999) The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48: 935-941
8. Karl D et al. (2007) Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol Ther [doi: 10.1089/dia.2006.0013]
9. SYMLIN® prescribing information: Amylin Pharmaceuticals [http://symlin.com/pdf/SYMLIN-pi-combined.pdf] (accessed 27 March 2007)
10. The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46: 271-286
11. Marrero DG et al. (2007) Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 30: 210-216